149 related articles for article (PubMed ID: 10506610)
1. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Lhommé C; Fumoleau P; Fargeot P; Krakowski Y; Dieras V; Chauvergne J; Vennin P; Rebattu P; Roche H; Misset JL; Lentz MA; Van Glabbeke M; Matthieu-Boué A; Mignard D; Chevallier B
J Clin Oncol; 1999 Oct; 17(10):3136-42. PubMed ID: 10506610
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Verschraegen CF; Levy T; Kudelka AP; Llerena E; Ende K; Freedman RS; Edwards CL; Hord M; Steger M; Kaplan AL; Kieback D; Fishman A; Kavanagh JJ
J Clin Oncol; 1997 Feb; 15(2):625-31. PubMed ID: 9053486
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
Look KY; Blessing JA; Levenback C; Kohler M; Chafe W; Roman LD
Gynecol Oncol; 1998 Sep; 70(3):334-8. PubMed ID: 9790784
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
Poon D; Chowbay B; Cheung YB; Leong SS; Tan EH
Cancer; 2005 Feb; 103(3):576-81. PubMed ID: 15612023
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
Nishio S; Shimokawa M; Tasaki K; Nasu H; Yoshimitsu T; Matsukuma K; Terada A; Tsuda N; Kawano K; Ushijima K
Gynecol Oncol; 2018 Sep; 150(3):432-437. PubMed ID: 30037491
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.
Sugiyama T; Yakushiji M; Noda K; Ikeda M; Kudoh R; Yajima A; Tomoda Y; Terashima Y; Takeuchi S; Hiura M; Saji F; Takahashi T; Umesaki N; Sato S; Hatae M; Ohashi Y
Oncology; 2000; 58(1):31-7. PubMed ID: 10644938
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Pitot HC; Wender DB; O'Connell MJ; Schroeder G; Goldberg RM; Rubin J; Mailliard JA; Knost JA; Ghosh C; Kirschling RJ; Levitt R; Windschitl HE
J Clin Oncol; 1997 Aug; 15(8):2910-9. PubMed ID: 9256135
[TBL] [Abstract][Full Text] [Related]
13. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Morise M; Niho S; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Sep; 44(9):846-51. PubMed ID: 25057092
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Bodurka DC; Levenback C; Wolf JK; Gano J; Wharton JT; Kavanagh JJ; Gershenson DM
J Clin Oncol; 2003 Jan; 21(2):291-7. PubMed ID: 12525521
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
Umesaki N; Fujii T; Nishimura R; Tanaka T; Nishida M; Fushiki H; Takizawa K; Yamamoto K; Hasegawa K; Izumi R;
Gynecol Oncol; 2004 Oct; 95(1):127-32. PubMed ID: 15385121
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Muggia FM; Blessing JA; McGehee R; Monk BJ
Gynecol Oncol; 2004 Aug; 94(2):483-7. PubMed ID: 15297192
[TBL] [Abstract][Full Text] [Related]
18. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.
Mühr-Wilkenshoff F; Hinkelbein W; Ohnesorge I; Wolf KJ; Riecken EO; Zeitz M; Scherübl H
Int J Colorectal Dis; 2003 Jul; 18(4):330-4. PubMed ID: 12774248
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.
Chamberlain MC
J Neurooncol; 2002 Sep; 59(2):157-63. PubMed ID: 12241109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
